---
title: Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
nct_id: NCT05397392
overall_status: RECRUITING
sponsor: Nanjing First Hospital, Nanjing Medical University
study_type: OBSERVATIONAL
primary_condition: Heart Failure
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05397392.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05397392"
ct_last_update_post_date: 2022-06-02
last_seen_at: "2026-05-12T07:20:12.414Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome

**NCT ID:** [NCT05397392](https://clinicaltrials.gov/study/NCT05397392)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1200
- **Lead Sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Conditions:** Heart Failure, Kidney Diseases, Kidney Injury, Heart Valve Diseases, Dialysis; Complications, Coronary Heart Disease
- **Start Date:** 2016-01
- **Completion Date:** 2027-12
- **CT.gov Last Update:** 2022-06-02

## Brief Summary

To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes

## Detailed Description

Cardiorenal syndrome is a clinical syndrome caused by acute or chronic injury of one of the heart and kidney resulting to acute or chronic dysfunction of the other organ. In recent years, the morbidity of cardiorenal syndrome has increased rapidly in China. Its condition is complex and difficult to treat. Due to the lack of studies specifically targeting the cardiorenal syndrome population, there is no systematic in-depth understanding of the pathogenesis and risk factors of this kind of disease. In clinic, the course of various types of cardiorenal syndrome is complex and difficult to be summarized into a specific type. Therefore, we intend to conduct a clinical systematic observation and research on such patients so as to optimize a more reasonable treatment scheme.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Patients meet the diagnosis of various types of cardiorenal syndrome according to the classification standards of various types formulated by KDIGO and ADQI expert consensus. Different syndromes were identified and classified into five subtypes. Acute CRS (type 1): acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and/or dysfunction. Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. Chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and/or dysfunction. Secondary CRS (type 5): systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney.

Exclusion Criteria:

Pregnant or breastfeeding women; Female patients with recent birth plans; Patients who cannot follow up on medications.
```

## Arms

- **acute kidney injury** — Acute kidney injury caused by heart disease or cardiac dysfunction due to acute renal damage
- **chornic kidney disease** — Chornic kidney injury caused by heart disease or cardiac dysfunction due to chronic kidney disease

## Interventions

- **guideline recommended routine treatment** (OTHER)

## Primary Outcomes

- **Hospitalization due to worsening of renal or cardiac function** _(time frame: 1 year)_ — eGFR continuously decreased by more than 25% within one year; NYHA cardiac function class III or above requires intravenous pharmacological agents; deterioration of cardiac or kidney function requiring dialysis
- **All-cause deaths** _(time frame: 1 year)_ — Deaths due to disease progression

## Secondary Outcomes

- **End-stage renal disease requires maintenance dialysis** _(time frame: 1 year)_
- **Acute kidney injury** _(time frame: 1 year)_

## Locations (1)

- Nanjing, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.|nanjing||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05397392.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05397392*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*